| Schedule of Related Party Transactions |
The
following is a summary of activity between the Company and Pharma and NDM for the three months ended June 30, 2019 and 2018, and
the year ended March 31, 2019. These amounts are unsecured, interest free, and payable on demand.
| | |
Three
Months Ended
June 30, 2019
(unaudited)
($) | |
Three
Months Ended
June 30, 2018
(unaudited)
($) | |
Year
Ended
March 31, 2019
($) |
| Balance
due to Pharma and NDM at beginning of period | |
| 964,679 | | |
| 613,818 | | |
| 613,818 | |
| Amounts
invoiced by DDL to Pharma | |
| — | | |
| — | | |
| (977 | ) |
| Amounts
invoiced by Pharma to DDL, NM and TCL (1) | |
| 435,416 | | |
| 521,085 | | |
| 2,312,412 | |
| Amounts
repaid by DDL to Pharma | |
| (305,060 | ) | |
| (308,434 | ) | |
| (1,569,496 | ) |
| Amounts
invoiced by B&W to DDL | |
| — | | |
| — | | |
| 2,206 | |
| Amounts
repaid by DDL to B&W | |
| — | | |
| — | | |
| (5,622 | ) |
| Foreign
exchange differences | |
| (22,359 | ) | |
| (68,920 | ) | |
| (84,843 | ) |
| Forgiveness
of payable accounted for as an equity contribution | |
| — | | |
| — | | |
| (302,819 | ) |
| Balance
due to Pharma and NDM at end of the period | |
| 1,072,676 | | |
| 757,549 | | |
| 964,679 | |
| (1) | These
amounts are included primarily in research and development expenses charged to the Company
by Pharma. |
|